Reducing Hereditary Cancer Act
- Sponsor
- Rep. Wasserman Schultz, Debbie [D-FL-25]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jul 23, 2025
Bottom line
The bill aims to enhance Medicare coverage for genetic testing, preventive surgeries, and more frequent screenings to reduce cancer risk in high-risk individuals.
What it actually does
This bill expands Medicare coverage to include hereditary cancer genetic testing for individuals with a family history of a hereditary cancer gene mutation or a personal/ancestral history suspicious for hereditary cancer. It also mandates Medicare coverage for certain risk-reducing surgeries and increases the frequency of evidence-based cancer screenings for individuals identified with a hereditary cancer gene mutation, all in accordance with nationally recognized clinical practice guidelines.
Proponents argue
Supporters argue that expanding Medicare coverage for hereditary cancer genetic testing and associated preventive measures is a crucial step towards personalized medicine, allowing for early detection and prevention of cancers in high-risk individuals. They contend that proactive intervention can save lives, improve quality of life, and potentially reduce long-term healthcare costs by preventing advanced-stage cancers.
Opponents contend
Critics might raise concerns about the potential increase in Medicare spending due to expanded coverage for genetic testing, surgeries, and more frequent screenings, especially without a specified funding mechanism. They may also question the administrative burden of interpreting and applying potentially conflicting 'least restrictive' clinical guidelines across different Medicare administrative contractors.
The bill is concise and can be read quickly, allowing sufficient time for an informed reader to understand its core provisions.
Section 2(a), (b), (c)
Medicare Coverage for Hereditary Cancer Genetic Testing
This section amends the Social Security Act to include 'germline mutation testing' as a covered Medicare service. This testing is for individuals who have a personal or family history of a hereditary cancer gene mutation or a history that suggests hereditary cancer. The testing must follow evidence-based clinical guidelines from major oncology organizations, with the least restrictive guidelines applying if there are conflicts. The bill also clarifies that such testing can be covered more than once if clinically necessary.
Supporters argue
Proponents argue that this provision is essential for identifying individuals at high risk for hereditary cancers, enabling early intervention and personalized prevention strategies. They believe it aligns Medicare with modern medical advancements in genetic science.
Critics contend
Opponents may argue that expanding genetic testing without clear cost controls could lead to significant increases in Medicare expenditures. They might also express concerns about the potential for over-testing or the administrative complexity of navigating multiple clinical guidelines.
Tradeoffs
The provision balances the benefit of early detection and personalized medicine against the potential for increased healthcare costs and administrative complexity in applying diverse clinical guidelines.
Section 3(a), (b)
Medicare Coverage for Certain Risk-Reducing Surgeries
This section adds a new subsection to the Social Security Act to ensure Medicare covers certain risk-reducing surgeries for individuals identified as high-risk for cancer based on genetic testing and clinical guidelines. These surgeries, such as prophylactic mastectomies or oophorectomies, are deemed 'reasonable and necessary' for treating illness, making them eligible for Medicare reimbursement. The intent is to cover surgeries that would reduce cancer risk for individuals with inherited mutations.
Section 4(a), (b), (c)
Increased Frequency of Evidence-Based Cancer Screenings
This section amends the Social Security Act to require Medicare to increase the frequency limitations for evidence-based cancer screenings for individuals who have been identified with a hereditary cancer (germline) gene mutation. The increased frequency must comply with nationally recognized clinical practice guidelines or be determined appropriate by the Secretary, but not less frequently than annually. Covered screenings include mammography, breast MRI, colonoscopy, and PSA testing, among others appropriate for high-risk individuals.
The definition of 'germline mutation testing' includes a clause stating that 'in the case of conflicting guidelines developed by more than one nationally recognized oncology professional organization, the least restrictive of such guidelines, as determined by such a medicare administrative contractor' shall apply.
Section 2(a)(2) and (nnn)
Why it matters:This is standard legislative practice for defining terms and setting parameters for implementation, though the 'least restrictive' clause is a significant policy choice.
Case for: Supporters argue that the 'least restrictive' clause ensures broader access to testing, preventing beneficiaries from being denied coverage due to differing interpretations or conservative guidelines from specific organizations. It prioritizes patient access.
Case against: Critics might argue that this clause could lead to increased costs and potentially unnecessary testing if the 'least restrictive' guidelines are overly broad. It also places a significant interpretive burden on Medicare administrative contractors.
Estimated impact: Likely increases the number of eligible individuals for genetic testing and potentially subsequent interventions compared to a scenario where the most restrictive guidelines applied.
The bill states that risk-reducing surgery is covered for an 'individual described in section 1861(s)(2)(II)'. However, 1861(s)(2)(II) currently refers to 'colorectal cancer screening tests.' Given the bill's context, it is highly probable this is a drafting error and should refer to the newly added 1861(s)(2)(KK) for germline mutation testing, or a similar provision identifying individuals with hereditary cancer gene mutations.
Section 3(a) amending Section 1862(p)
Why it matters:This appears to be a drafting oversight or typographical error rather than an intentional burial. Such errors can lead to significant ambiguity in implementation.
Case for: Proponents would argue that the clear intent of the bill should guide interpretation, and that the reference should be understood to mean individuals identified with hereditary cancer gene mutations. They would advocate for a technical correction if the bill moves forward.
Case against: Critics could argue that strict adherence to the statutory text would limit coverage for risk-reducing surgeries to individuals undergoing colorectal cancer screening, which would largely negate the purpose of this section. This ambiguity could lead to legal challenges or inconsistent coverage.
Estimated impact: If interpreted strictly, it would severely limit the scope of preventive surgeries covered. If interpreted by intent, it would cover a broad range of surgeries for high-risk individuals.